(-)-7-(2.4-dichlorophenyl)-2,6-dimethvl-N-[(1R)-1-methylpropyl]pyrrolo[1,2-b]pyridazin-4-amine | 684215-16-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: (-)-7-(2.4-dichlorophenyl)-2,6-dimethvl-N-[(1R)-1-methylpropyl]pyrrolo[1,2-b]pyridazin-4-amine
• 英文别名: N-[(2R)-butan-2-yl]-7-(2,4-dichlorophenyl)-2,6-dimethylpyrrolo[1,2-b]pyridazin-4-amine
• CAS: 684215-16-5
• 化学式: C₁₉H₂₁Cl₂N₃
• 分子量: 362.302
• InChiKey: AAFVYQILLYWXPB-GFCCVEGCSA-N

物化性质

• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Pyrrrolo[1,2-b]pyridazine compounds and their uses
  申请人：——

  公开号：US20040138221A1

  公开（公告）日：2004-07-15

  Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I): 1 including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R 1 and R 2 are independently selected from H, Me or OMe.

  本发明揭示了新型CRF受体拮抗剂及其用于治疗多种疾病，包括表现为CRF高分泌或与CRF或CRF受体相关的疾病，如焦虑和抑郁症。本发明的CRF受体拮抗剂具有以下结构（I）的结构：1包括立体异构体或立体异构体混合物、药学上可接受的前药或其药学上可接受的盐，其中在公式（I）中，R1和R2独立选择自H、Me或OMe。
• EP1615929A1
  申请人：——

  公开号：EP1615929A1

  公开（公告）日：2006-01-18
• US7074791B2
  申请人：——

  公开号：US7074791B2

  公开（公告）日：2006-07-11
• [EN] PYRROLO[1,2-B]PYRIDAZINE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSES DE PYRROLO[1,2-B]PYRIDAZINE ET LEURS UTILISATIONS
  申请人：UPJOHN CO

  公开号：WO2004092176A1

  公开（公告）日：2004-10-28

  Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including dissorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I), including stereoisomersr or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R1 and R2 are independently selected from H, Me or Ome.